Bio-Rad Laboratories Cash Flow Statement
NYSE: BIOIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bio-Rad Laboratories free cash flow
In fiscal 2025, Bio-Rad Laboratories generated $532.2 million of operating cash flow and spent $157.6 million on capital expenditures. That left free cash flow of $374.6 million, a free-cash-flow margin of 14.5% of revenue. Free cash flow was up 29.4% from the prior year's $289.6 million.
Bio-Rad Laboratories returned $295.5 million to shareholders through share repurchases, equal to 79% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Bio-Rad Laboratories cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 759.90M | -1.84B | -637.30M | -3.63B | 4.25B | 3.81B | 1.76B | 365.61M | 122.25M | 26.00M |
| Net Income growth (YoY) | — | — | — | -185.27% | +11.54% | +116.88% | +381.02% | +199.07% | +370.19% | -77.01% |
| Depreciation & Amortization | 165.40M | 151.60M | 145.90M | 137.30M | 137.60M | 138.60M | 134.20M | 138.10M | 148.70M | 142.90M |
| Stock-Based Compensation | 58.00M | 62.30M | 61.30M | 60.90M | 51.20M | 41.60M | 35.60M | 27.80M | 23.40M | 19.70M |
| Change in Working Capital | 88.50M | 24.70M | -34.90M | -246.20M | 25.70M | -67.10M | 25.80M | 46.80M | -111.80M | -44.60M |
| Operating Cash Flow | 532.20M | 455.20M | 374.90M | 194.40M | 669.46M | 584.97M | 457.90M | 285.49M | 104.14M | 216.07M |
| Capital Expenditures | -157.60M | -165.60M | -156.70M | -112.80M | -133.75M | -108.56M | -98.53M | -129.82M | -111.33M | -141.44M |
| Investing Cash Flow | -189.70M | -160.20M | 20.20M | -1.21B | -797.38M | -69.89M | -208.89M | -186.98M | -175.57M | -213.88M |
| Share Repurchases | -295.50M | -203.60M | -428.70M | -215.70M | -50.00M | -100.00M | -28.00M | -48.91M | -2.92M | 0 |
| Debt Issued | — | 0 | 0 | 1.19B | 0 | 0 | — | — | — | — |
| Debt Repaid | -500.00K | -400.00K | -500.00K | -500.00K | -3.02M | -426.94M | -643.00K | -2.96M | -316.00K | -303.00K |
| Financing Cash Flow | -283.20M | -218.80M | -425.60M | 973.60M | -55.43M | -523.04M | -22.76M | -48.68M | 341.00K | 9.02M |
| Net Change in Cash | 42.40M | 85.40M | -30.10M | -36.60M | -195.98M | 4.46M | 228.49M | 49.18M | -72.44M | -1.28M |
| Free Cash Flow | 374.60M | 289.60M | 218.20M | 81.60M | 535.72M | 476.41M | 359.37M | 155.67M | -7.20M | 74.63M |
This table shows 10 annual periods of Bio-Rad Laboratories's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BIO's reporting calendar. What is a cash flow statement?